Sort
4,870 grants matching “glp 1”
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
$1,657,121Mone Zaidi · Icahn School Of Medicine At Mount Sinai · U01 · FY2022 · AG
A reversible aptamer based therapeutic to treat stroke
$1,656,236Richard Joseph Shea · Basking Biosciences · R44 · FY2021 · HL
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
$1,654,767Mone Zaidi · Icahn School Of Medicine At Mount Sinai · U01 · FY2023 · AG
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
$1,652,369Mone Zaidi · Icahn School Of Medicine At Mount Sinai · U01 · FY2024 · AG
rAAV-CNGB3 Gene Therapy for Achromatopsia: Translational Research Studies
$1,646,469William W Hauswirth · University Of Florida · R24 · FY2013 · EY
Developing autologous iPSC-RPE based IND for AMD patients
$1,644,542Kapil Bharti · National Eye Institute · ZIA · FY2018 · EY
Molecular Pathogenesis of Neoplasia
$1,639,115John Heiss · National Institute Of Neurological Disorders And Stroke · ZIA · FY2021 · NS
Drug development of RK-33 for breast cancer treatment
$1,634,811Farhad Vesuna · Natsar Pharmaceuticals, Inc. · R44 · FY2025 · CA
EARLY CLINICAL DEVELOPMENT OF MODIFIED P8 FOR THE TREATMENT OF ALZHEIMER'S DISEASE
$1,633,354Nazneen N Dewji · Cenna Biosciences, Inc. · R44 · FY2025 · AG
Regulatory Science Core
$1,633,070Maria Elena Bottazzi · University Of California-Irvine · U19 · FY2024 · AI
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
$1,616,919Mone Zaidi · Icahn School Of Medicine At Mount Sinai · U01 · FY2025 · AG
rAAV-CNGB3 Gene Therapy for Achromatopsia: Translational Research Studies
$1,613,805William W Hauswirth · University Of Florida · R24 · FY2017 · EY
In vitro pharmacology, chronic toxicology, and embryo-fetal development studies to demonstrate safety of GSM-779690
$1,612,640Douglas R Galasko · University Of California, San Diego · U01 · FY2025 · AG
IND-Enabling Pre-clinical Development of Modified P8 for the Treatment of Alzheimer's Disease
$1,610,358Nazneen N Dewji · Cenna Biosciences, Inc. · R44 · FY2021 · AG
Preventing invasive prostate cancer
$1,607,348Raymond C Bergan · University Of Nebraska Medical Center · R01 · FY2025 · CA
DEVELOPMENT OF SAPONIN DMLT ADJUVANT (SDA)
$1,602,685Elizabeth Norton · Tulane University Of Louisiana · N01 · FY2023 · AI
Nonalcoholic Steatohepatitis: Natural History, Pathogenesis and Therapy
$1,598,965Yaron Rotman · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
DEVELOPMENT OF SAPONIN DMLT ADJUVANT (SDA)
$1,598,870Elizabeth Norton · Tulane University Of Louisiana · N01 · FY2024 · AI
Core--Vector
$1,595,516Jaap Goudsmit · Beth Israel Deaconess Medical Center · U19 · FY2007 · AI
Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain
$1,585,395Pierre Riviere · Peptide Logic, Llc · R44 · FY2019 · DA
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
$1,583,667Katherine N Cahill · Vanderbilt University Medical Center · U01 · FY2024 · AI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
$1,583,667Katherine N Cahill · Vanderbilt University Medical Center · U01 · FY2025 · AI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
$1,583,667Katherine N Cahill · Vanderbilt University Medical Center · U01 · FY2023 · AI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
$1,583,667Katherine N Cahill · Vanderbilt University Medical Center · U01 · FY2021 · AI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
$1,583,667Katherine N Cahill · Vanderbilt University Medical Center · U01 · FY2022 · AI